• Calumide<sup>®</sup>

Calumide®

Bicalutamide

Description
Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or
removes the source of androgen.

Indications
Bicalutamide 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.

Supply
Each commercial box contains 3X10’s tablets in Alu-Alu blister pack.

 

Related Products